ASX:ILAPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
ISLAND PHARMACEUTICALS ORD
$0.450
$0.025 (5.26%)
Day Range
$0.445 - $0.480
52 Week Range
$0.120 - $0.630
Volume
222.26K
Avg Volume (10D)
592.59K
Market Cap
$114.28M
Price Chart
Market Statistics
Open$0.480
Previous Close$0.475
Day High$0.480
Day Low$0.445
52 Week High$0.630
52 Week Low$0.120
Valuation
Market Cap114.28M
Shares Outstanding253.96M
Price to Book16.92
Trading Activity
Volume222.26K
Value Traded100.08K
Bid$0.445 × 4,933
Ask$0.475 × 100,000
Performance
1 Day-5.26%
5 Day7.14%
13 Week-1.10%
52 Week164.71%
YTD4.65%
Technical Indicators
RSI (14)58.20
50-Day SMA$0.417
200-Day SMA$0.337
Latest News
Biotechnology
Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding
Island Pharma expands antiviral pipeline with Burnet Institute; NHMRC grant of over $780k to back ISLA-101, accelerating Galidesivir MVD program.
1 min read
Biotechnology
Island Pharma Partners with USAMRIID and Geneva Foundation for Galidesivir under FDA Animal Rule
Island Pharma signs a 3-year CRADA with USAMRIID and Geneva Foundation to fast-track Galidesivir for Marburg under FDA Animal Rule, eyeing NDA.
1 min read
Biotechnology
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
1 min read
Biotechnology
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
1 min read